AbbVie Inc (NYSE:ABBV)., a leading biopharmaceutical company, stands at a critical juncture as it navigates the loss of ...

AbbVie (NYSE:ABBV) has managed to keep its market share for its bestselling arthritis therapy, Humira, above 70%, generic ...

AbbVie (ABBV) continues to dominate the adalimumab market with 72% share in the U.S., despite biosimilar threats gaining ground. Read more here.

High-yield dividend stocks may not appeal to some investors. Three Motley Fool contributors have identified some especially great high-yield dividend stocks to buy in 2025 -- and all of them are big ...

Korean drugmakers hold over 50% market share in the 6 best-selling biosimilar markets, 2 companies sign exclusive licensing ...

The company's immunology portfolio, led by Skyrizi and Rinvoq, continues to thrive despite Humira's patent expiration, ...

Medtronic has been raising its dividend for 47 consecutive years and it offers a high yield now. Bristol Myers Squibb offers ...

Alvotech (ALVO), a commercial-stage global biotech company specializing in the development and manufacture of biosimilar medicines, ...

This week, the department of pharmaceuticals (DoP) said the Indian arm of US firm AbbVie violated the newly amended Uniform Code for Pharmaceutical Marketing Practices. What did AbbVie do, and ...

Stagnant sales for Bristol Myers Squibb’s Sotyktu have raised questions about whether the tyrosine kinase 2 (TYK2) inhibitor can achieve blockbuster status, let alone the $4 billion peak sales ...

AbbVie and Amgen experienced sell-offs after unimpressive phase 2 data. Both companies continue to record strong financial results and have exciting pipelines. Both have grown their dividends at a ...